CorMedix Inc (NASDAQ: CRMD) stock closed at $3.80 on 11/16/23 after a major increase of 14.1%. The stock has been weak relative to the market over the last nine months but has risen 18.4% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, CRMD is expected to continue to be Value Creation neutral.
CorMedix has a current Value Trend Rating of F (Lowest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. CorMedix has a slightly negative Power Rating of 35 and a very low Appreciation Score of 7, leading to the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment